Artificial Intelligence: A Magic Pill That Can Solve Any Disease For Which There Is No Cure Yet
"Hope around AI is justified because the advances we have been making in areas like deep learning and reinforcement learning have been spectacular, outstripping even our optimistic projections," he added.
India has a unique opportunity to leap ahead with Artificial Intelligence (AI) in healthcare, as well as to bring the powers of cloud and AI to the broader world, a top Microsoft executive said on Wednesday.
According to Peter Lee, Corporate Vice President for Microsoft Healthcare, India has a well-laid infrastructure and advanced technology base, which “is an important crucible for innovation and healthcare”.
“There is an opportunity here in India, that’s unique in the world, to leap ahead by designing systems for the service of people to enable better reach for healthcare in rural parts of India and to bring the powers of cloud and AI to the broader world,” Lee said.
He stated that new ideas, such as using predictive analytics to detect people at risk of cardiac disease early, or to predict onset of blindness due to uncorrected refractive error in kids, are taking root in India, and can be beneficial for even the most far off world communities.
AI has been increasingly seen as a magic pill that can solve any disease for which there is no cure yet.
Besides providing doctors and nurses with new user experiences, AI has a tremendous potential in precision medicine. It can also make healthcare more accessible and affordable for people in the remotest of areas, Lee said.
“Hope around AI is justified because the advances we have been making in areas like deep learning and reinforcement learning have been spectacular, outstripping even our optimistic projections,” he added.
While privacy of healthcare remains a big issue globally, Microsoft does not own the data but instead provides it as a foundation to create models that would be in the service of our customers, Lee said.
“At Microsoft, we take privacy so seriously that our attention to data compliance regulations is absolutely the best in the industry,” he added. (IANS)
Breast cancer in men is rarely seen. It shares many similarities with cancer of the breast in women but there are some important differences too.
Male breast cancer represents between 0.5 and 1 per cent of all breast cancers diagnosed each year. Higher rates of male cancer in central and eastern Africa may be related to higher liver infectious diseases that lead to hypoestrogenism.
Dr Kumardeep Dutta Choudhury, Senior Consultant & Head of Department, Dept of Medical Oncology (IOSPL), Fortis Hospital, Noida, shares the facts you need to know about it.
Risk factors associated with breast cancer in men:
Genetics and family history
Family history of cancer in a first-degree relative is associated with an increased risk of breast cancer among men. Approximately 15 to 20 per cent of men with breast cancer have a family history of the disease compared with only 7 per cent of the general male population.
The risk is higher with inherited BRCA2 rather than BRCA1 mutations. Other genes which have been associated with an increased risk of breast cancer in men are PTEN tumor suppressor gene (Cowden syndrome), tumor protein p53 (TP53; Li-Fraumeni syndrome), partner and localizer of BRCA2 (PALB2), and mismatch repair genes (Lynch syndrome).
Alterations of the estrogen to androgen ratio
Excessive estrogen stimulation may be due to hormonal therapies (e.g., estrogen-containing compounds or testosterone), hepatic dysfunction, obesity, marijuana use, thyroid disease, or an inherited condition, such as Klinefelter syndrome may increase risk of male breast cancer.
Primary testicular conditions
Testicular conditions may increase risk of breast cancer in men include orchitis, undescended testes (cryptorchidism), and testicular injury.
Male breast cancer has been diagnosed at a more advanced stage than female breast cancer, due to a lack of awareness. They generally present with a painless, firm mass that is usually subareolar, with nipple involvement in 40 to 50 percent of cases. The left breast is involved slightly more often than the right, and less than 1 percent of cases are bilateral. There may be associated skin changes, including nipple retraction, ulceration, or fixation of the mass to the skin or underlying tissues. Axillary nodes are typically palpable in advanced cases.
Most histologic subtypes of that cancer seen in women are also present in men, men with breast cancer are rarely diagnosed with lobular carcinomas is due to lack of acini and lobules in the normal male breast, although these can be induced in the context of estrogenic stimulation.
Approach to treatment in men is same as that for women. However, role of breast conserving surgery is limited because of small volume of breast tissue. In hormone receptor-positive disease, we give adjuvant tamoxifen rather than an aromatase inhibitor (AI), because of insufficient evidence to support AI monotherapy for men. If there are contraindications to tamoxifen (e.g., hypercoagulable state), an AI with GnRHa may be administered. AIs do not reduce testicular production of estrogens, that’s why GnRHa is administered concurrently with AI. They are treated with mastectomy, radiotherapy, chemotherapy and hormone therapy.
Limited data suggest these patients are at an increased risk of a contralateral breast cancer, but absolute risk is low. They are also at risk for secondary malignancies and 12.5 percent may develop a second primary cancer. The most common types were gastrointestinal, pancreas, non-melanoma skin, and prostate cancer.
Ten-year disease-specific survival rates for histologically negative nodes – 77 and 84 per cent, one to three positive nodes – 50 and 44 per cent and four or more histologically positive nodes – 24 and 14 per cent. (IANS)